Chronic Fatigue Syndrome Clinical Trial
Official title:
Inspiratory Flow Dynamics During Sleep in Gulf War Syndrome (GWS) and the Effect of Continuous Positive Airway Pressure (CPAP)
Verified date | December 2014 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The purpose of this study is to determine any sleep disordered breathing in veterans with
Gulf War Syndrome (GWS) and compare it to healthy normal asymptomatic Gulf War veterans.
This study will also determine the effect of treatment with continuous positive airway
pressure on veterans with Gulf War Syndrome.
1. The investigators hypothesize that sleep complaints (insomnia, un-refreshing sleep and
daytime fatigue) among GWS patients are related to increased sleep fragmentation
secondary to the presence of sleep disordered breathing in GWS patients.
2. The investigators hypothesize that increased collapsibility of the upper airway during
sleep with the development of inspiratory flow limitation (IFL) and sleep disordered
breathing causes the increased sleep fragmentation in GWS patients.
3. The investigators hypothesize that correction of IFL and sleep disordered breathing in
GWS patients will result in an improvement of their sleep quality resulting in an
improvement of their sleep complaints and other functional symptoms.
Status | Completed |
Enrollment | 29 |
Est. completion date | November 2010 |
Est. primary completion date | October 2008 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 32 Years to 52 Years |
Eligibility |
Inclusion Criteria: - First Gulf War veterans with and without the syndrome - Males - Between 32 and 52 years of age - No history of current alcoholism nor opiate use - No history of current active depression nor post-traumatic stress disorder (PTSD) Exclusion Criteria: - Females - History of active alcoholism or opiate drug use - History of active depression and PTSD |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | VA Medical Center, Northport | Northport | New York |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Amin MM, Belisova Z, Hossain S, Gold MS, Broderick JE, Gold AR. Inspiratory airflow dynamics during sleep in veterans with Gulf War illness: a controlled study. Sleep Breath. 2011 Sep;15(3):333-9. doi: 10.1007/s11325-010-0386-8. Epub 2010 Aug 12. — View Citation
Amin MM, Gold MS, Broderick JE, Gold AR. The effect of nasal continuous positive airway pressure on the symptoms of Gulf War illness. Sleep Breath. 2011 Sep;15(3):579-87. doi: 10.1007/s11325-010-0406-8. Epub 2010 Aug 19. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of Fatigue Symptom | Fatigue- increasing impact was rated 1-7 using the fatigue severity scale on days 1 and 7 averaged, where 1= no fatigue and 7= severe fatigue. | 3 weeks treatment with either therapeutic or sham CPAP | No |
Primary | The Prevalence of Inspiratory Flow Limitation (IFL) During Sleep in GWS. | IFL was determined by plotting inspiratory flow against supra-glottic pressure for each breath sampled during continuous stage 2 sleep on a full night polysomnogram on both veterans with GWS and asymptomatic gulf war veterans. We expressed the prevalence of inspiratory flow limitations during sleep as the percentage of flow limited breath in the sample of both GWS and asymptomatic gulf was veterans. |
On a full night polysomnogram | No |
Secondary | Change of Pain Complaint | Pain- increased level were rated 0-10 by visual analogue scale, where 0= no pain and 10= severe pain. We compared the change of pain symptom before and after treatment of either 3 weeks on therapeutic nasal CPAP or sham nasal CPAP |
3 weeks of treatment on either therapeutic or sham nasal CPAP | No |
Secondary | Change of Cognitive Dysfunction | Cognition dysfunction- increasing difficulty with memory, ability to think, and ability to concentrate was rated 0-10 daily by visual analogue scale, where 0 no problem and 10=severe problems. | 3 weeks treatment with either therapeutic or sham CPAP | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454683 -
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT01686074 -
Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT02075489 -
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
|
N/A | |
Completed |
NCT01651754 -
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT00540254 -
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00071162 -
Genetics of Fibromyalgia
|
N/A | |
Withdrawn |
NCT04870476 -
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
|
N/A | |
Completed |
NCT05730660 -
Quercetin Phytosome® Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT04542161 -
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT03807973 -
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
|
Phase 1 | |
Recruiting |
NCT05719493 -
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
|
N/A | |
Recruiting |
NCT05967052 -
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
|
Phase 2 | |
Terminated |
NCT01730495 -
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01650636 -
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
|
N/A | |
Completed |
NCT01156909 -
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01046370 -
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT06128967 -
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
|
Phase 3 | |
Completed |
NCT02669212 -
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
|
N/A | |
Not yet recruiting |
NCT06011135 -
Exploring Worry in CFS/ME
|